文献速递眼底病与葡萄膜炎

雷珠单抗0.5 mg治疗少见病因所致黄斑水肿的疗效与安全性:PROMETHEUS研究12个月结果

Efficacy and Safety of Ranibizumab 0.5 mg for the Treatment of Macular Edema Resulting from Uncommon Causes: Twelve-Month Findings from PROMETHEUS.
PubMed 文献 · Ophthalmology · 2018-01-20

PROMETHEUS是一项3期、12个月、双盲、随机、假注射对照、多中心研究,纳入178例非糖尿病、非视网膜静脉阻塞、非新生血管性年龄相关性黄斑变性所致黄斑水肿的成人患者,按2:1随机接受雷珠单抗0.5 mg(n=118)或假注射(n=60)。主要终点第2个月最佳矫正视力(BCVA)变化显示雷珠单抗优于假注射(最小二乘均值+5.7字母 vs +2.9字母,单侧P=0.0111),治疗效应+2.8字母;第12个月雷珠单抗组平均BCVA增益9.6字母,但不同病因亚组间治疗效应存在差异。

要点

  • 第2个月BCVA最小二乘均值变化雷珠单抗组+5.7字母 vs 假注射组+2.9字母,治疗效应+2.8字母(单侧P=0.0111)。
  • 第12个月雷珠单抗组平均BCVA增益9.6字母。
  • 炎症/葡萄膜炎所致及白内障术后黄斑水肿患者BCVA治疗效应>1行。

核心结论

  • 主要终点达成,雷珠单抗在少见病因所致黄斑水肿中BCVA增益优于假注射,第2个月治疗效应为+2.8字母。
  • 第12个月雷珠单抗组平均BCVA增益较高(9.6字母),但不同病因亚组间治疗效应存在差异,炎症/葡萄膜炎所致或白内障术后黄斑水肿患者BCVA治疗效应>1行。
  • 总体雷珠单抗耐受性良好,至第12个月无新安全性发现。

研究设计与样本

  • 3期、12个月、双盲、随机、假注射对照、多中心研究。
  • 纳入178例年龄≥18岁的 eligible 患者,随机2:1接受雷珠单抗0.5 mg(n=118)或假注射(n=60),基线及第1个月给药;自第2个月起两组均接受基于疾病活动的开放标签个体化雷珠单抗治疗。
  • 对5种预设基线黄斑水肿病因(炎症性/葡萄膜炎性、人工晶状体眼或无晶状体眼、中心性浆液性脉络膜视网膜病变、特发性、其他)的主要终点进行预设亚组分析。
  • 156例患者(87.6%)完成研究。

主要发现

  • 基线至第2个月,雷珠单抗组BCVA最小二乘均值变化+5.7字母 vs 假注射组+2.9字母(单侧P=0.0111),治疗效应+2.8字母。
  • 基线至第12个月,雷珠单抗组平均BCVA增益9.6字母。
  • 第2个月治疗效应在5种预设病因亚组间存在差异,范围从>5字母增益至0.5字母丢失。
  • 安全性发现与雷珠单抗已确立的安全性特征一致。

关键数值与推荐

  • 主要终点:基线至第2个月BCVA(ETDRS字母)变化。
  • 雷珠单抗组第2个月BCVA最小二乘均值+5.7字母 vs 假注射组+2.9字母,单侧P=0.0111,治疗效应+2.8字母。
  • 雷珠单抗组第12个月平均BCVA增益9.6字母。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 第2个月治疗效应在5种预设病因亚组间存在差异,范围从>5字母增益至0.5字母丢失。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the efficacy and safety of ranibizumab 0.5 mg in adult patients with macular edema (ME) resulting from any cause other than diabetes, retinal vein occlusion, or neovascular age-related macular degeneration. DESIGN: A phase 3, 12-month, double-masked, randomized, sham-controlled, multicenter study. PARTICIPANTS: One hundred seventy-eight eligible patients aged ≥18 years. METHODS: Patients were randomized 2:1 to receive either ranibizumab 0.5 mg (n = 118) or sham (n = 60) at baseline and month 1. From month 2, patients in both arms received open-label individualized ranibizumab treatment based on disease activity. A preplanned subgroup analysis was conducted on the primary end point on 5 predefined baseline ME etiologies (inflammatory/post-uveitis, pseudophakic or aphakic, central serous chorioretinopathy, idiopathic, and miscellaneous). MAIN OUTCOME MEASURES: Changes in best-corrected visual acuity (BCVA; Early Treatment Diabetic Retinopathy Study letters) from baseline to month 2 (primary end point) and month 12 and safety over 12 months. RESULTS: Overall, 156 patients (87.6%) completed the study. The baseline characteristics were well balanced between the treatment arms. Overall, ranibizumab showed superior efficacy versus sham from baseline to month 2 (least squares mean BCVA, +5.7 letters vs. +2.9 letters; 1-sided P = 0.0111), that is, a treatment effect (TE) of +2.8 letters. The mean BCVA gain from baseline to month 12 was 9.6 letters with ranibizumab. The TE at month 2 was variable in the 5 predefined etiology subgroups, ranging from >5-letter gain to 0.5-letter loss. The safety findings were consistent with the well-established safety profile of ranibizumab. CONCLUSIONS: The primary end point was met and ranibizumab showed superiority in BCVA gain over sham in treating ME due to uncommon causes, with a TE of +2.8 letters versus sham at month 2. At month 12, the mean BCVA gain was high (9.6 letters) in the ranibizumab arm; however, the TE was observed to be variable across the different etiology subgroups, reaching a >1-line TE in BCVA in patients with ME resulting from inflammatory conditions/post-uveitis or after cataract surgery. Overall, ranibizumab was well tolerated with no new safety findings up to month 12.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Staurenghi G, Lai TYY, Mitchell P, et al. Efficacy and Safety of Ranibizumab 0.5 mg for the Treatment of Macular Edema Resulting from Uncommon Causes: Twelve-Month Findings from PROMETHEUS. Ophthalmology. 2018. PMID: 29371007. doi:10.1016/j.ophtha.2017.12.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。